Enzolytics Inc (ENZC)

[falon]

Because they DOT their i and CROSS their t ENZC is the place to be!


ENZC is very thorough is their execution of their business plan and communicating to shareholders. They tell you what they are going to do, they do it and they tell you what they did.

What is ENZC going to do?

1. Enzolytics, Inc, a drug development company with a focus on debilitating infectious diseases, announced on September 16, the execution of a non-binding letter of intent to merge with BioClonetics Immunotherapeutics, Inc. a biotechnology company located in Dallas Texas, USA.

2. The Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates.

3. Thereafter, PBMC based in-vitro neutralization studies will be conducted with the Enzolytics ITV-1 peptide in combination with the BioClonetics Clone 3 antibodies. Based on the results, the best combination with be tested in primate studies at the California National Primate Research Center University of California, Davis, California.

4. BioClonetics has been invited by the National Science Foundation (NSF) to submit an application for funding for development of anti-SARS-Cov-2 monoclonal antibodies using its proprietary technology. Such application to the NSF and a corresponding application to the NIH are now pending.

5. ENZC is in the process of compiling the information to bring current its OTC filings. The company has several additional initiatives which it will work towards the remainder of 2020 and into 2021. The company has begun the process of identifying a clinical research organization for the preparation of pre-IND protocols for submission to the FDA.

6. The Company is also looking to expand its medical advisory board with individuals that have direct experience taking medical products through the regulatory process and bringing them to market. The Company's intent is to take the ITV-1 treatment, which has already successfully completed Phase III clinical trials at the Specialized Hospital for Active Treatment of Infectious and Parasite Diseases in Sofia, Bulgaria, through the permitting process and begin the process of gaining regulatory approval with the FDA in the United States.

7. The proposed merger anticipated in the non-binding LOI will result in Charles Cotropia being appointed as CEO of the merged entity and Harry Zhabilov and Joseph Cotropia, MD, being appointed as co-CSO. Gaurav Chandra, MD, will serve as COO of the merged entity. Additional details will be disclosed as the transaction progresses.

8. Enzolytics, Inc. (OTC PINK:ENZC) (or the "Company") today announced the execution of a binding letter of intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") a biotech company located in Dallas Texas, replacing the earlier non-binding letter signed on September 12, 2020.

9. All of our steps are taken with two objectives in mind. First our focus is on creating successful therapeutics against infectious diseases, including HIV and now our focus on the Coronavirus. Secondly, our efforts are also intended to increase the value of our technology and the value of our company - which directly translates into value for our investors. Please know that these are our two guiding objectives with every effort we make.

10. Our plans are to test in combination the Enzolytics ITV-1 peptide in conjunction with our anti-HIV monoclonal antibodies. There is reason to believe that there will be synergistic effect achieved with this combination therapy.

11. As we have reported earlier, we have applications pending with the National Institute of Health (NIH) and the National Science Foundation (NSF) for further development of our anti-HIV monoclonal antibodies and our proposed production of anti-SARS-CoV-2 (Coronavirus) antibodies. These applications are being reviewed now. Without regard to the success or lack of success of these applications, our combination of technologies with Enzolytics will provide funding for our direct progress with the precise proposals now submitted to the NIH and NSF. As outlined in detail in these applications, we will use our proprietary methodology to produce additional monoclonal antibodies against HIV that specifically target conserved, immutable sites on the virus. Recall that others, including the NIH in conjunction with Vaccine Research Center attempted for years to produce monoclonal antibodies against HIV and failed because of "virus escape" – a euphonism for the fact that their antibodies targeted a site that mutates allowing the virus to "escape" over time.

12. In addition, management of ENZC is scheduling a meeting with a GMP manufacturer anticipated to take place before the end of the month.
13. We are making great progress on our plans to further develop additional anti-HIV monoclonal antibodies and to now begin the production of fully human monoclonal antibodies targeting the CoronaVirus. On December 1, we are expanding our lab to the campus of Texas A&M University at its Institute for Preclinical Studies. This expansion will allow us to complete production of monoclonal antibodies against both the HIV virus and the CoronaVirus and collaborate with the biopharma experts on the campus. Although we have NIH grant applications pending for the production of anti-HIV and anti-CoronaVirus monoclonal antibodies, we have secured funding that allows us to proceed without delay.

14. Enzolytics, Inc. (OTC PINK:ENZC or the "Company") has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States.

15. Currently, the Company has requested proposals from several PCAOB accounting firms to provide quotes for Audits of the Company's current and prior year Financial Statements in order to become fully reporting. Bids were requested to be provided by mid-January, and the Company anticipates making a decision by the end of January 2021.

What has ENZC done?

1. Enzolytics and BioClonetics merged.

2. NSF and NIH applications submitted.

3. Submitted financial reports to get ENZC current and got current.

4. Appointed Dr. Ronald Moss to Medical Advisory Board.

5. Appointed Charles Cotropia CEO.

6. Appointed Harry Zhabilov and Joseph Cotropia, MD as co-CSO.

7. Increased the value of our technology and the value of our company.

8. Provided funding for on-going operations.

9. Set up Lab at Texas A&M University Institute for Preclinical Studies.

10. Accepted a proposal from a Houston based PCAOB Audit firm to Audit the Company's year-end financial statements.


It is all in ENZC press releases:

What ENZC is going to do.

What ENZC has done.

What ENZC has told its Shareholders what it has accomplished.

All in black and white and GREEN all over!!!

ENZC News and Press, Enzolytics Inc

Coronavirus Targeted Epitopes Claimed in Enzolytics' Pending Patent Applications are Verified as Fully Conserved in the UK, Brazil and South African Variants of the Coronavirus (SARS-COV-2)
COLLEGE STATION, TX / ACCESSWIRE / April 5, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (or the "Company"). In a significant development, recent findings have revealed that the monoclonal antibodies being produced by the Company against targeted sites on the Coronavirus are directed against epi...

April 05, 2021 10:00:00 am | ACCESSWIRE |
Enzolytics Announces the Filing of Updated NIH Grant Applications Incorporating Newly Identified Conserved Epitopes on Both the HIV-1 and SARS-CoV-2 Viruses; Other Corporate Updates
COLLEGE STATION, TX / ACCESSWIRE / March 22, 2021 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") today announced it has filed NIH grant applications seeking funding for its production of monoclonal antibodies targeting the identified conversed epitope sites on both the HIV-1 and the SAR...

March 22, 2021 08:00:00 am | ACCESSWIRE |
Enzolytics Finalizes Documentation with International Medical Partners, Ltd for Clinical Trials and Initial Production of ITV-1 Company Also Provides Update on Year End Reporting
COLLEGE STATION, TX / ACCESSWIRE / March 16, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the formalization of corporate legal documents pursuant to Articles of Association forming International Medical Partners ("IMPL") a Bulgarian Limited Liability Company ...

March 16, 2021 09:00:00 am | ACCESSWIRE |
Enzolytics Is Surrounded By Controversy And Could Be Worthless
The company recently merged with BioClonetics and plans to develop treatments for HIV and COVID-19. However, there are no revenues and its Bulgarian partner denies that Enzolytics has a stake in it. Enzolytics has a valuation of $982.1 million but I don’t think the business...

March 15, 2021 11:32:52 am | SeekingAlpha |
Enzolytics Announces the Discovery and Patenting of 8 Newly Identified Conserved Target Sites on the HIV-1 Virus
Production of monoclonal antibodies targeting these sites is in process. U.S. patent protection has been filed claiming these sites. COLLEGE STATION,TX / ACCESSWIRE / March 8, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") today announced it has filed for patent protection on t...

March 08, 2021 09:00:00 am | ACCESSWIRE |
Hot Reddit Penny Stocks For Your Watch List In March 2021
Reddit Penny Stocks Continue Surging But Are They Worth The Risk? The stock market continues selling off today and many penny stocks weren’t immune to this drop either. Even some of the sectors that tend to perform well in environments like this were seen pulling back during Frid...

March 05, 2021 12:40:15 pm | PennyStocks.com |
Enzolytics Announces the Discovery and Patenting of Eleven Newly Identified Conserved Target Sites on the SARS-CoV-2 Virus (Coronavirus)
Production of Monoclonal Antibodies Targeting These Sites Is in Process in the Company's Texas Lab COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced it has identified eleven conserved, expectedly immutable sites...

February 22, 2021 10:30:00 am | ACCESSWIRE |
Enzolytics Updates Permitting Progress in Europe on Its Planned Clinical Trials of Its Patented ITV-1 Anti-HIV and Other Developments
COLLEGE STATION, TX / ACCESSWIRE / February 22, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today announced the execution of Articles of Association to form International Medical Partners ("IMPL") a Bulgarian Limited Liability Company of which the Company is 50% owner. The ...

February 22, 2021 09:15:00 am | ACCESSWIRE |
Enzolytics Inc. Reports Test Results of its Patented ITV-1 Conducted at the National Centre of Infectious and Parasitic Diseases
COLLEGE STATION, TX / ACCESSWIRE / February 16, 2021 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the results of an in vitro study of the Company's ITV-1/IPF peptide treatment that demonstrated the broad efficacy with low toxicity. The Company's ITV-1 peptide was test...

February 16, 2021 09:00:00 am | ACCESSWIRE |
Enzolytics Announces The Discovery Of Seven Newly Identified Conserved Target Sites On The HIV Virus
Company begins process of identifying conserved/immutable target sites on SARS-CoV-2 (the CoronaVirus) and other developments COLLEGE STATION, TX / ACCESSWIRE / February 1, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today announced it has identified seven additional conserve...

Enzolytics, Inc. Engages PCAOB Auditor for December 31, 2020 Year End Audit
COLLEGE STATION, TX / ACCESSWIRE / January 11, 2021 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today, announced it has accepted a proposal from a Houston based PCAOB Audit firm to Audit the Company's year-end financial statements, subject to the receipt and acceptance of the en...

January 11, 2021 10:00:00 am | ACCESSWIRE |
Enzolytics, Inc. 2020 Year End Update
COLLEGE STATION, TX / ACCESSWIRE / December 30, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") today shared the following update provided by Enzolytics' CEO Charles Cotropia. The full content of the update is presented below. "December 30, 2020 To Our Shareholders, On Septe...

December 30, 2020 12:30:00 pm | ACCESSWIRE |
Enzolytics, Inc. Engages BTS Research to Conduct Toxicity Study
PLANO, TX / ACCESSWIRE / December 14, 2020 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") has engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tes...

December 14, 2020 10:40:00 am | ACCESSWIRE |
Enzolytics, Inc. Files Provisional Patent for Treatment of Multiple Sclerosis
PLANO, TX / ACCESSWIRE / December 10, 2020 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") today announced the filing of a provisional patent with the U.S. Patent Office on December 9, 2020 for a treatment of Multiple Sclerosis developed by Harry Zhabilov, titled NUCLEAR PROTEINS ISOLAT...

December 10, 2020 01:30:00 pm | ACCESSWIRE |
Enzolytics, Inc. Completes Merger with BioClonetics Immunotherapeutics, Inc.
PLANO, TX / ACCESSWIRE / December 1, 2020 / Enzolytics, Inc. (OTC Markets "ENZC" or the "Company") announced the execution of the definitive business combination agreement successfully merging the biotech companies Enzolytics, Inc. and BioClonetics Immunotherapeutics, Inc. on World AIDS Day....

December 01, 2020 10:15:00 am | ACCESSWIRE |
Enzolytics Inc. Shares Current BioClonetics Immunotherapeutics, Inc. Update
PLANO, TX / ACCESSWIRE / November 13, 2020 / Enzolytics Inc. (OTC PINK:ENZC) or the "Company" today shared the following update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics"), resulting from the application of proceeds from the initial fundi...

November 13, 2020 09:00:00 am | ACCESSWIRE |
Enzolytics, Inc. Appoints Ronald Moss, M.D. to Its Medical Advisory Board
Offers Update on OTC Disclosure Filings and Initial Funding PLANO, TX / ACCESSWIRE / November 10, 2020 / Enzolytics, Inc. (OTC PINK:ENZC) or the "Company" announced the appointment of Ronald Moss, M.D., to the Medical Advisory Board of the Company. Dr. Moss has an extensive 25-year bac...

November 10, 2020 09:00:00 am | ACCESSWIRE |
Enzolytics, Inc. Announces Appointment of Charles Cotropia as CEO of ENZC and Harry Zhabilov as Its CSO
Enzolytics announces the procurement of funding for initial operations of merging entity PLANO, TX / ACCESSWIRE / October 22, 2020 / Enzolytics, Inc. (OTC PINK:ENZC) (or the "Company") announced the appointment, by the Board of Directors of the Company, on October 20 of Charles Cotropia...

October 22, 2020 09:00:00 am | ACCESSWIRE |
Enzolytics, Inc. Shares BioClonetics Immunotherapeutics, Inc. Company Update
Enzolytics provides guidance on engagement of manufacturer and OTC Markets Membership PLANO, TX / ACCESSWIRE / October 19, 2020 / Enzolytics, Inc. (OTC PINK:ENZC)( "ENZC" or the "Company") today shared the update provided by ENZC's Merger target BioClonetics Immunotherapeutics, Inc. ("B...

October 19, 2020 09:00:00 am | ACCESSWIRE |
Enzolytics, Inc. Announces Execution of Binding Letter of Intent for Merger with BioClonetics Immunotherapeutics, Inc.
PLANO, TX / ACCESSWIRE / October 14, 2020 / Enzolytics, Inc. (OTC PINK:ENZC) (or the "Company") today announced the execution of a binding letter of intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") a biotech company located in Dallas Texas, re...

October 14, 2020 09:00:00 am | ACCESSWIRE

Enzolytics, Inc. Announces Execution of Binding Letter of Intent for Merger with BioClonetics Immunotherapeutics, Inc.
PLANO, TX / ACCESSWIRE / October 14, 2020 / Enzolytics, Inc. (OTC PINK:ENZC) (or the "Company") today announced the execution of a binding letter of intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") a biotech company located in Dallas Texas, re...

October 14, 2020 09:00:00 am | ACCESSWIRE |
Enzolytics, Inc. Announces New Board Member, Charles Cotropia, CEO of BioClonetics Immunotherapeutics, Inc. Harry Zhabilov CEO of Enzolytics to Join Board of BioClonetics
PLANO, TX / ACCESSWIRE / October 1, 2020 / Enzolytics, Inc. (OTC PINK:ENZC) or (the "Company") today announced the addition of Charles Cotropia to the Company's Board of Directors. ENZC entered into a Letter of Intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or...

October 01, 2020 09:00:00 am | ACCESSWIRE |
Enzolytics, Inc. Announces Execution of Letter of Intent with BioClonetics Immunotherapeutics, Inc. (With Additional Update on 2020 Initiatives)
PLANO, TX / ACCESSWIRE / September 16, 2020 / Enzolytics, Inc. (OTC PINK:ENZC or the "Company") today announced the execution of a non-binding letter of intent (the "LOI") to merge with BioClonetics Immunotherapeutics, Inc. ("BCLS" or "BioClonetics") a biotech company located in Dallas Texas...

September 16, 2020 09:00:00 am | ACCESSWIRE |
Enzolytics Update
PLANO, TX / ACCESSWIRE / April 16, 2020 / Enzolytics- (OTC PINK:ENZC) is pleased to update shareholders on the current corporate initiatives. The company has retained SEC counsel for the purpose of updating all corporate information, financials and to bring the company current from a public ...

Enzolytics Comments on Recent Market Activity and Shareholder Update
DALLAS, TX / ACCESSWIRE / February 6, 2020 / Enzolytics- (OTC Pink Sheet-ENZC) was notified by FINRA that an unauthorized press release titled, "Enzolytics Inc., Launches Coronavirus Prevention Kit" was distributed to the public. Enzolytics and its management had no knowledge of this press r...
April 16, 2020 09:00:00 am | ACCESSWIRE


LINK to ENZC Press Releases
https://marketwirenews.com/stock/enzc/news/